1 / 65

SEPSIS - MENINGITIS - MALARIA

SEPSIS - MENINGITIS - MALARIA. Pr. B. Vandercam Consultation Maladies Infectieuses et Tropicales Cliniques Universitaires St-Luc Octobre 2004 . Sepsis. Focus Absence of focus Purpura fulminans Community acquired sepsis immunocompentent adult Nosocomial sepsis immunocompetent adult

loyal
Télécharger la présentation

SEPSIS - MENINGITIS - MALARIA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SEPSIS - MENINGITIS - MALARIA Pr. B. Vandercam Consultation Maladies Infectieuses et Tropicales Cliniques Universitaires St-Luc Octobre 2004

  2. Sepsis • Focus • Absence of focus • Purpura fulminans • Community acquired sepsis immunocompentent adult • Nosocomial sepsis immunocompetent adult • IV DU • Asplenic (anatomic or functional) • Neutropenia • Toxic shock syndrome

  3. Working definitions associated with sepsis and related disorders

  4. Source of infection • Anamnesis (pets, travel, household, …) • Physical examination (purpura, scar …) • Blood culture Urine culture RX thorax Echo (scan abdo) obstacle abscess collection Echo cardio

  5. Activated protein C (- 6 %) • Corticosteroids (low (HC 200-300 mg/day) - long (5-7d)) • Intensive insuline therapy (- 17%) • Volume resuscitation (- 15%)

  6. Prior medicare database analyses • MEEHAN T. Jama 1997; 278:2080 Mortality increased significantly with delay in first Abx dose > 8 hrs (registration to dose) • GLEASON PP. Arch Intern Med 1999, 159:2562 Mortality based on abx (OR) Cephalosporin 1.0 Cephalosporin + mac 0.76 Fluoroquinolone 0.64

  7. Method : review of Medicare database for patients > 65 yrs hospitalized with x-ray confirmed CAP • Period reviewed : July ’98 - March ’99 • Patients : 13 771 • PSI score : III - 47 % IV - 24 %

  8. Results

  9. Skin lesions and systemic infections

  10. Purpura fulminans : treatment • Cefotaxime 2 gr q 4 - 6 h or Ceftriaxone 2 gr q 12 h • Allergy Vanco 1 gr q 12 h + Aztreonam 2 gr q 6 h or Moxifloxacin 0,4 gr q 24 h or Levofloxacin 0,5 gr q 12 h

  11. Community acquired sepsis - immunocompetent adults • Infecting organisms • Enterobacteriacae • Staph aureus • Strept pneumoniae & spp • N. meningitidis • Bacteroides spp • Treatment • Cefotaxime or Ceftriaxone • Amoxi clav or cefurox + amino

  12. IVDU • Infecting organisms • Staph aureus • Exclude endocarditis • Previous antibiotherapy • Treatment Oxacilline 2 gr q 6 h or Vancomycine 1 gr q 12h + Genta 2,5 mg/kg q 12 h

  13. Asplenia • Overwhelming sepsis • Stand by therapy • Amoxi clav • Allergy, travel --> Moxifloxacin, Levofloxacin • Vaccination • Antibioprophylaxis

  14. Asplenia sepsis • Infecting organisms • S. pneumoniae • H. influenzae • N. meningitidis • Capnocytophaga spp • Treatment • Ceftriaxone or Cefotaxime

  15. Nosocomial *sepsis - immunocompetent adult • Infecting organisms • Enterobacteriacae • S. aureus • Strep pneumoniae • Bacteroïdes spp • P. aeruginosa • CNS * readmission - nursing home

  16. Nosocomial sepsis • Local epidemiology • Colonization • Previous antibiotherapy • IV line • Urinary catheter • Invasive procedure

  17. Treatment • Vancomycin ? • Cefotaxime or Ceftriaxone or Pip/tazo + amino • Ceftazidime or Cefepime or Carbapenem + amino

  18. Sepsis neutropenia • Infecting organisms • Strepto spp • CNS • S. aureus • Enterobacteriacae • P. aeruginosa • Colonization • Previous antibiotherapy

  19. Neutropenia « Low risk » Amoxi clav 2 gr q 6-8 h + Cipro 750 q 12 h OR Ceftriaxone 2 gr q 12 h + Amikacin 15-25 mg/kg q 24 h

  20. Neutropenia « High risk » • Ceftazidime 2 gr q 8 h • Cefepime 2 gr q 8 h • Pip/tazo 4 gr q 6 h • Imipenem 750 mg q 6 h • Meropenem 2 gr q 8 h + amino ???

  21. Toxic shock syndrome • Infecting organisms • Strepto A, B, C, • Staph aureus • Treatment • Cefazoline 2 gr q 8 h + Clindamycine 600 mg q 8 h

  22. Clinical diagnosis • Fever sensitivity 85% • Menigism 70% • Altered mental status 60% • Kernig Sensitivity 5% Specificity 95% Poser la question = y répondre

  23. Case presentation • 25-year-old man • 2-day history of severe headache, fever, neck stiffness • 38,3 °C • No rash • Normal mental status and neurologic examination • Pain on neck flexion but able to flex his neck fully • No Kernig and Brudzinski signs

  24. Contraindications of lumbar puncture • Known or suspected space-occupying lesions with mass effect  LP deferred until CT scan • Severe uncorrected coagulopathy (INR > 1.5) • Trombocytopenia (platelet count < 50 000/mm³) • Infection at the puncture site (decubitus ulcer) - Glasgow < 13 - Shock

  25. When should a computerized tomography scan precede a lumbar puncture ? • Age over 60 years • Immunocompromised state • History of primary neurologic disease, head trauma, neurosurgery • History of seizure within the past week • Altered mental status, cilated or poorly reactive pupils, occular palsy and focal neurologic abnormalities • Papilledema, bradycardia, irregular respiration • History of cancer • Suspicion of brain abscess (endocarditis, bacteremia …) Empiric anti infective therapy without delay

  26. CSF examination • Gram stain - Ziehl - Ink • Culture (bacteria, fungi, brucella, nocardia …) • Bacterial antigens • if antibiotherapy • Gram or culture negative • PCR virus + BK • Blood culture 60 % + in acute bacterial meningitis

  27. CSF characteristics in selected neurologic conditions

  28. Purpura, petechia  N. meningitidis • Cellulitis face  S. aureus H. influ • VRS, VRI  S. pneumoniae H. influ • Parotitis  Mumps • Endocarditis  S. aureus • Septic arthritis  S. pneumoniae S. aureus • Pregnancy  Listeria

  29. Acute meningitis treatment • IV line - blood cultures • AB + dexa 10 mg within 30 min(*) • LP if no contraindication • Chest x-ray • Delta scan if needed (*) S. pneumoniae : 4 h N. meningitidis : 2 h LCR

  30. Antibiotherapy • Listeria : ampi or CTX • S. pneumoniae : peni i 10% cef 3 i 1% • H. influ :  vaccination

  31. Antibiotherapy dosage Penetration - bactericide - CMI • Cefotax 2 gr -(4 gr) q 4h (ratio 25%) • Ceftriaxone 2 gr q 12h (ratio 15 - 30%) • Ampi 2 gr q 4h (ratio 10 - 15%) • Cefepime (ratio 10%) • Ceftazidime (ratio 20 - 40%) • Cotrimoxazole (ratio 30 - 35%)

  32. Antibiotic therapy in meningitis • IV from the beginning to the end … • Standard therapy • 7 days for N. meningitidis • 10 - 14 days for S. pneumoniae • (14) - 21 days for L. monocytogenes

  33. Meningitis : child > 3 months - adults < 50 yrs • Infecting organisms • S. pneumoniae • N. meningitidis • H. influ • L. monocytogenes • Treatment • Cefotaxime + ampicilline • Ceftriaxone + ampicilline

  34. Meningitis : alcoohol - adults < 50 yrs Cellular immune deficiency - Debilitating illness • Infecting organisms • S. pneumoniae • L. monocytogenes • N. meningitidis • Gram negative bacilli • Treatment • Cefotaxime + ampicilline • Ceftriaxone + ampicilline

  35. Meningitis : HIV /AIDS • Infecting organisms • C. neoformans • S. pneumoniae • M. tuberculosis • L. monocytogenes • T. pallidum • N. meningitidis • HIV

  36. Meningitis : cerebrospinal fluid shunt • Infecting organisms • Coag neg staph • S. aureus • Diphteroids • Enterobacteriaceae • Treatment • Vancomycin + cefta

  37. Meningitis : after cranial or spinal trauma • Infecting organisms • S. pneumoniae • H. influ • Treatment • Cefotaxime or Ceftriaxone

  38. Meningitis after cranial or spinal trauma (> 4 days) • Infecting organisms • Enterobacteriaceae • S. aureus • P. aeruginosa • S. pneumoniae • Treatment • Vancomycin + ceftazidime

  39. People on the move: demographics year 2003 • 175 million persons live outside of their country of origin (2,9%) of the world's population • Population of concern to UNHCR: 21,6 million • Refugees 11,7 million • Internally displaced persons: 20-30 million • Rural to urban migration: 20-30 million/year • 1-2 million migrate permanently every year • 700 million tourist arrivals/year

  40. Malaria risk pyramid for 1 month of travel without chemoprophylaxis • Oceania 1:5 • Africa 1:50 • South Asia 1:250 • Southeast Asia 1:2500 • South America 1:5000 • Mexico and Central America 1:10 000 01643

  41. Délai d’apparition de malaria selon espèce Schwartz NEJM 2003; 349, 1510

  42. Malaria en Belgique Institut de Santé Publique-Louis Pasteur

More Related